Fresh conflict is developing in the ongoing struggle between branded pharmaceutical products and their generic cousins. Many companies choose to manufacture generic versions themselves taking advantage of their own facilities and expertise. As a successfully branded drug is targeted by generics manufacturers. It is difficult for small companies to adopt a strategy of seeking companies’ intent on genericising products. Hence, this would enable deals to be made in an amicable manner.